Silver Book Fact

Of the 8 million older Americans at high risk of developing advanced age-related macular degeneration (AMD), 1.3 million will develop advanced AMD within 5 years. However, the NEI-sponsored Age-Related Eye Disease Study (AREDS) nutritional formula could help 300,000 of those 1.3 million avoid the severe vision loss of advanced AMD over a 5-year period.

Bressler N, Bressler S, Congdon N, Ferris F, et al. Potential Public Health Impact of Age-Related Eye Disease Study Results: AREDS report no. 11. Arch Opthalmol. 2003; 121(11): 1621-4. http://jamanetwork.com/journals/jamaophthalmology/fullarticle/415852

Reference

Title
Potential Public Health Impact of Age-Related Eye Disease Study Results: AREDS report no. 11
Publication
Arch Opthalmol
Publication Date
2003
Authors
Bressler N, Bressler S, Congdon N, Ferris F, et al
Volume & Issue
Volume 121, Issue 11
Pages
1621-4
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Family risk of glaucoma
    “‘Five of my nine brothers and sisters had glaucoma,’ says 81-year-old Jean R. who for 20 years has depended on eye drops to decrease pressure inside her eyes. Jean is…  
  • It has been estimated that monthly use of ranibizumab in individuals with age-related macular degeneration (AMD) would reduce the incidence of legal blindness by 72% and visual impairment by 37%,…  
  • Lucentis to treat wet age-related macular degeneration (AMD)
    An FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)–ranibizumab (Lucentis)–maintained vision in 95% of clinical trial participants and improved vision by 15 or more letters in approximately 25%…  
  • In general, every 10 mmHg reduction in systolic blood pressure reduces the risk of diabetes complications by 12%.  
  • Nearly 50% of diabetic retinopathy patients who received ranibizumab–an anti-VEGF drug–experienced substantial visual improvement after a year of injections